Montreal, Quebec – August 15, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced today FDA clearance of its Investigational New Drug application (IND) …
Trending at Lumira Ventures
Expanding Pipeline Leads to Name Change – LQT Therapeutics Now Thryv Therapeutics
New Name Emphasizes Relentless Pursuit of an Expanded and Rare Disease Portfolio Oncology Programs added to existing Long QT Syndrome Program (“LQTS”) Additional US$15M Financing Provides Fuel for Proof-of-Concept in LQTS LAVAL, Québec, Canada | 11 July 2022 | Thryv …
LQT Therapeutics Announces Collaboration with Leading Cancer Researcher
LQT Therapeutics, Inc. (“LQTT”) is pleased to announce a collaboration with the laboratory of Dr. Donald McDonnell of Duke University School of Medicine to evaluate LQTT SGK1 inhibitors as potential treatment for patients with resistant prostate and breast cancer. Despite …
LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT Syndrome
Closing the gap between industry and academia to place patients directly at the center of research efforts. LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project, “SILENCE-LQTS: SGK1 inhibition as a novel therapeutic …
LQT Therapeutics Announces the Appointment of Dr. Robert Booth to its Board of Directors
Company Strategically Strengthens its Fight Against Long QT Syndrome with Novel Kinase Drug Development Expertise Today, LQT Therapeutics, Inc. (LQTT) announced the addition of Dr. Robert Booth to its Board of Directors. Dr. Booth brings more than 30 years of biopharmaceutical …
Lumira Ventures invests in LQT Therapeutics US$19M Series A financing to advance lead compound through Phase 1
LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi …